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Abstract: Inflammation is the mainstay of atherosclerosis and is an important governing factor at all stages of the disease 
process from lesion formation to plaque build-up and final end-stage rupture and thrombosis. An overview of the numer-
ous clinico-epidemiological studies on the association between inflammatory gene polymorphisms and Cardiovascular 
disease (CVD) and its co-morbidities have shown that the risk associated with any single genotype is modest while the 
haplotypes, especially those defined on the basis of tag-SNP approach, have better coverage of the gene and show moder-
ately higher impact on disease risk. Nevertheless, even these associations have been inconsistent with low cross-race  
repeatability. This has been attributed to many plausible causes such as clinical heterogeneity, sample selection criteria, 
variable genetic landscapes across different ethnic groups, confounding effect of co-morbidities etc. On the other hand, 
unbiased studies such as the family-based linkage and case-control based associations that have taken into account, thou-
sands of genotypic markers spanning the whole genome, have had the ability to identify novel genetic loci for coronary 
artery  disease.  These  studies  have  shown  that  many  inflammatory  genes  are  involved  in  the  regulation  of  specific  
biomarkers  of  inflammation  that  collectively  contribute  to  the  disease-associated  risk.  In  addition,  there  appears  to  
be  considerable  cross  talk  between  the  different  biochemical  and  metabolic  processes.  Therefore,  consideration  of  
all these factors can build towards an ‘atherosclerotic bionetwork’ that can refine our quest for developing a robust risk 
stratification tool for cardiovascular disease. 
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INTRODUCTION 
  Inflammation plays a pivotal role in the atherosclerotic 
disease process and is considered to be a primary modulator 
of disease risk [1]. Inflammatory cells present in the arterial 
lesions mediate the various processes of plaque formation, 
progression and vessel thrombosis. Plasma levels of several 
inflammatory biomarkers are associated with future cardio-
vascular  risk  in  a  variety  of  clinical  settings.  Sustained  
low-grade  inflammatory  process  can  be  implicated  in   
enhanced atherothrombosis in certain ethnic groups such as 
the  South  Asian,  Afro-Caribbean  and  Hispanic  and  can  
influence  the  efficiency  of  cardiovascular  drug  treatments 
(statins  as  well  as  aspirin)  [2,  3].  The  seminal  role  of  
inflammation in atherosclerosis dates back to more than 70 
years and predates the cholesterol hypothesis. The inflamma-
tory perspective gained preeminence in 1999 with the claim 
that atherosclerosis is primarily an inflammatory disease [1]. 
Proof of concept for this hypothesis was initially provided by 
Ridker  and  colleagues  who  showed  that  despite  elevated 
baseline levels of various upstream markers of inflammation 
and  immune  response  in  CAD  patients,  high  sensitive  C  
Reactive Protein (hsCRP) stood out as the best predictor of  
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disease risk. In  their study, healthy  men who developed  a 
new  cardiovascular  event  during  8-year  follow-up  showed 
baseline CRP levels in the top quartile and were three times 
at  higher  risk  of  developing  future  Myocardial  Infarction 
(MI) and twice at risk for ischemic stroke as compared to 
men  in  the  bottom  quartile  [4].  In  2000,  the  same  group 
showed a similar trend in a 3-year prospective study on post-
menopausal  women  [5].  Over  twenty  or  more  large-scale 
prospective studies have subsequently shown that the rela-
tive impact of hsCRP is at least as large as that individually 
of low-density lipoprotein cholesterol, high-density lipopro-
tein cholesterol, blood pressure, or smoking. Knowledge of 
hsCRP was able to correctly reclassify a substantial propor-
tion of "intermediate-risk" individuals into clinically relevant 
higher- or lower-risk categories in  these studies [6].  Risk-
prediction  models  that  incorporate  hsCRP,  such  as  the  
Reynolds Risk Score, have improved risk classification and 
accuracy  for  global  risk  prediction,  particularly  for  those 
deemed at "intermediate risk" by usual algorithms, such as 
the Framingham Risk Score [7]. Statins, which are primarily 
advocated  as  lipid-lowering  drug,  have  been  also  credited 
with  anti-inflammatory  properties  [8].  However,  clinical 
trials  that  are  into  investigating  the  long-term  benefits  of 
statins such as the JUPITER [9] and PROSPER [10] have 
shown discrepant findings on the additional value of CRP as 
a risk predictor in comparison to the prevailing conventional 
predictors of risk. The outcome of clinical trials is governed 
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key consideration. Results from other ongoing clinical trials 
on the efficacy of statin in targeting lipids, inflammation and 
overall reduction in cardiovascular disease (CVD) risk can 
bring  about  better  clarity  in  this  matter.  A  comprehensive 
overview on the pivotal role of inflammation and its down-
stream reaction sequale in atherosclerosis from the formation 
of fatty streak and progression to complex plaque and finally 
plaque rupture that involves various triggers of the inflam-
matory process has been lucidly described [11, 12].  
  Interleukin 6 (IL6) is an important pleiotropic cytokine 
that has a broad range of humoral and cellular immune prop-
erties relating to inflammation, host defense and tissue injury 
[13] and contributes to the clinical evolution of CVD. IL6 is 
the principle mediator of acute-phase response and primary 
determinant of CRP production by the liver [14]. Although 
high levels of IL6 have been implicated with future risk of 
MI event [5, 15, 16], presence of high correlation between 
IL6  and  CRP  levels  undermines  the  independent  value  of 
IL6  in  many  instances.  Additionally,  CRP  has  a  inherent 
stable nature, lacks diurnal variation and is easy to assay and 
hence scores over many other biomarkers of inflammation as 
the most valuable predictor of CVD risk [17] and as a useful 
adjunct for global risk assessment in the primary prevention 
of CVD [18]. 
  Some of the other common pro inflammatory cytokines 
include the Tumor necrosis factor 1 (TNFα) produced by the 
activated  macrophages  and  the  Interleukin1  (IL1)  released 
by  the  macrophages,  platelets  and  injured  endothelium. 
These cytokines act through the recruitment of monocytes / 
macrophages  to  the  vessel  wall  thus  eliciting  increased  
expression  of  adhesion  molecules  such  as  Monocyte  
Chemoattractant  Protein  1  (MCP-1)  and  synthesis  of 
prothrombotic factors such as Plasminogen activator inhibi-
tor 1 (PAI1) and von Willebrand factor, that promotes plaque 
vulnerability and ensuing thrombotic events etc. 
  The aim of this review is to provide an overview of the 
possible  associations  of  single  nucleotide  polymorphisms 
(SNPs) in inflammatory genes implicated in atherosclerosis. 
While there are multiple genes that regulate the inflamma-
tory process, we have chosen to elaborate on three key genes 
in the central inflammatory pathway with emphasis on large 
studies, primarily to highlight the reported pattern of geno-
type-disease association as well as to understand the genetic 
and environmental factors that influence these outcome such 
that  appropriate  study  design  and  methodology  may  be 
adopted that adequately address the prevailing lacunae and 
help in the planning of robust research strategies in future.  
INFLAMMATORY GENES POLYMORPHISMS 
  Single  nucleotide  polymorphisms  in  genes  relating  to 
inflammation have been linked to enhanced risk of CVD but 
the risk associated with any one genotype has been consid-
ered to be modest. Taking into consideration, the high allele 
frequency  for  many  of  the  variants  in  the  constitution  of 
haplotypes, multiple ‘risk alleles’ may have a larger impact 
on  the  regulation  of  gene  activity  and  function  [19]  as  
well as in the modulation of clinically significant risk [20].  
A  number  of  studies  have  reported  the  association  of  
single  nucleotide  polymorphisms  (SNPs)  in  candidate  
genes of inflammation with plasma biomarker, CVD and its 
co-morbidities.  An  overview  on  the  genotype-phenotype 
associations of three of the well-studied inflammatory genes 
that belong to the central inflammatory process are provided 
in Table 1. 
IL6 Gene Polymorphisms 
  Polymorphisms  in  the  promoter  region  of  the  IL6  
regulate  the  expression  and  inter  individual  variability  
of  plasma  IL  6  in  a  complex,  interactive  and  haplotype-
dependent manner [19]. Five common promoter SNPs in the 
IL6 gene have been shown to be in strong equilibrium with 
each  other  using  pair-wise  Linkage  Disequilibrium  (LD) 
analysis [21]. Independently and in combination, these pro-
moter SNPs has been associated with various pathological 
states of CVD and its co-morbidities. In a recent report on a 
predisposed  cohort  of  Asian  Indians,  a  risk  haplotype, 
GGAAG, defined by these promoter SNPs was shown to be 
associated with over 3.7 times risk of CAD (OR 3.676, 95% 
CI 1.68 – 8.05, P = 0.0017) and a population attributable risk 
of 21.1% [22]. 
  The –174G>C variant (rsID1800795) has been the most 
widely  studied  promoter  SNP  and  both  the  G  and  the  C  
alleles have been independently associated with CVD and its 
co-morbidities. The C allele was associated with higher basal 
plasma IL6 levels [23, 24] and showed over 1.34 times risk 
of MI in the ECTIM study on 640 patients and 719 controls 
[25]. Levels of IL6 were shown to reach their peak, 6 hours 
following  bypass  surgery,  particularly  among  C  allele  
carriers [24]. Among the WOSCOPS cohort, comprising of 
498 MI patients who were followed up for 4.8 year, response 
to  Pravastatin  was  better  among  individuals  with  CC  
genotype  who  also  exhibited  a  significant  lowered  risk  of 
CHD as compared to the placebo treatment group (OR 0.46, 
95% CI-0.27-0.79, P=0.019) [26]. The C allele has also been 
significantly  associated  with  the  following  disease  states  - 
higher systolic BP in men with BMI >24.86 kg/m2; higher 
risk of CHD among smokers [27]; increased arterial stiffness 
in the Rotterdam study [28] and elevated HSP60 levels in the 
KORA 2000 study [29]. 
  On the other hand, the G allele has been associated with 
increased cerebrovascular events and severe disability post 
event in the Rotterdam study [30], increased secretion of IL6 
and reduced  insulin sensitivity  in  type 2 diabetic subjects, 
increased  correlation  between  adipose  IL6  mRNA  expres-
sion  and  insulin  resistance  in  morbidly  obese  individuals 
[31], increased Intima-Media Thickness ( IMT) in middle-
aged  men  without  exercise  induced  ischemia  [32],  risk  of 
peripheral  arterial  disease  (PAD)  in  Ty2DM  patients  [33] 
and abnormalities in lipid metabolism [34]. 
  In  contrast  to  the  above  findings,  the  large  MONICA 
survey on Bavarian residents have shown no association of 
the –174G>C SNP with any of the traditional risk factors nor 
prevalence of MI [35], while the Turkish case-control report 
on  a  small  cohort  of  120  CAD  patients  and  105  controls 
showed that this polymorphisms does not contribute to the 
risk stratification [36]. In one of the largest report to date on 
2691 Ty2DM patients and 2238 controls from the Nurses’ 
Health Study and the Health professional follow-up study, 
no association was shown between diabetes and any of the 
five IL6 promoter SNPs, which was additionally verified by 
comprehensive  meta  analysis  ([21].  Genotype-phenotype 
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variability in the pattern of association of either the G or C 
allele of the –174G>C [37] with stroke. 
  With  regard  to  the  other  promoter  variants  in  the  IL6 
gene, the G allele of the –572 G>C SNP was associated with 
MI in a Han Chinese population [38], with a RR of 1.652 for 
CHD in  another  Chinese  study [39] and with plasma IL6, 
CRP and fibrinogen in CAD patients in a Korean study [40]. 
Ex vivo stimulation of leukocytes by LPS showed elevated 
baseline levels of IL6  among carriers of the G  allele in  a 
study involving both –597G>A (rs1800797) and –174G>A 
SNPs [41].  
  The  underlying  reasons  for  these  inconsistencies  in  
study findings are manifold. Primarily, IL6 has a complex 
physiology with both pro-and anti-inflammatory properties 
and complex pattern of transcriptional regulation. Presence 
of  clinical  heterogeneity,  lack  of  stringent  phenotype  
definition  of  cases  and  controls  and  presence  of  co-
morbidities hinder the identity of true causal verses casual 
effects. Other plausible issues relating to genetic factors such 
as Hardy Weinberg Equilibrium (HWE), allele frequencies, 
influence of neighboring genetic variants and time of sample 
collection  can  also  influence  the  outcome  of  the  study  
findings. 
CRP Gene Polymorphisms 
  Baseline  CRP  level  is  influenced  by  genetic,  environ-
mental and clinical factors [42]. CRP shows a heritability of 
27%-  40%,  indicating  considerable  influence  of  genetic 
regulation on this trait [43, 44]. In an in-depth analysis of 
over thirteen lead SNPs selected using the tag-SNP approach 
in  3301  participants  from  the  Framingham  Heart  Study 
(FHS),  Kathiresan  S  et  al.  identified  one  triallelic  SNP 
+1444C>T>A  (rsID3091244)  in  the  promoter  region  that 
was  significantly  associated  with  high  CRP  levels 
(p<0.0001). However, this SNP was able to independently 
account for only 1.4% of the variation in CRP levels while 
twelve of the clinical correlates explained up to 26% of the 
variability, BMI being prominent among them [45]. In yet 
another large investigation of over 7159 subjects from the 
Third NHANES cohort comprising of mixed ethnic groups, 
two SNPs, rs3093058 and rs3091244 were associated with 
high CRP levels and two SNPs, rs1205 and rs2808630 with 
low CRP levels. After adjusting for covariates and post-hoc 
analysis, only rs3091244 SNP was associated with prevalent 
CAD,  particularly  in  the  non-Hispanic  White  population 
[46]. In a more recent analysis of data pooled from 5 differ-
ent  studies  comprising  of  4610  CAD  patients  and  over 
Table 1.  Overview of Genotype-Phenotype Association of some key Inflammatory Genes Variants 
Genes  SNP  rsID  Vascular Events  Surrogate Biomarkers 
IL6  -174G>C  rs1800795  CAD/MI [22, 26, 27]  High plasma IL6 levels [24] 
         CIMT [32]  High CRP levels [22, 52, 53, 55]  
         PAD [33]  High Systolic Blood pressure [27] 
            Increased arterial stiffness [28] 
            Insulin insensitivity [84]  
            Lipid abnormalities [34] 
   -572G>C  rs1800796  CAD / MI [38]   High plasma IL6 levels [24] 
            Plasma IL6, CRP, Fibrinogen [54] 
CRP  +1444C>T  rs3091244  CAD [46]  High plasma CRP levels [42, 45, 52, 85, 86]  
         Stroke [87]   Hypertension [47] 
            Obesity [50] 
      rs3093058     High Plasma CRP levels [86] 
      rs3091244     High Plasma CRP levels [49] 
      rs1800947  Arterial pulse-wave velocity [49]    
TNF-α  -308G>A  rs3091256  CAD [58, 60, 61, 66, 67]     
            Obesity [63] 
            Insulin resistance [64] 
            Metabolic syndrome [62] 
            Plasma CRP levels [65] 
CAD – Coronary Artery Disease, CIMT – Carotid Intima Media Thickness, CRP- C-reactive protein, IL 6 – Interleukin 6, MI- Myocardial Infarction, PAD – Peripheral Arterial 
Disease, SNP – Single Nucleotide Polymorphism, TNF- α – Tumor necrosis factor-alpha.  
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14,000 non-CAD subjects, it was observed that although the 
rs3091244  variant  was  significantly  associated  with  high 
CRP levels, there was no association with risk of CHD, par-
ticularly  after  adjusting  for  confounders.  This  SNP  along 
with  other  variants  have  been  associated  with  CRP  levels 
and hypertension in the  Turkish study [47], with Ischemic 
stroke  in  a  Chinese  study  [48],  with  arterial  pulse-wave  
velocity  in  a  Japanese  cohort  [49]  and  with  obesity  in  a  
Taiwanese cohort [50]. However, in the Segovia study on a 
Spanish  population,  although  four  SNPs  (rs1417938, 
rs1800947, rs1130864, rs1205) were significantly associated 
with CRP levels after adjusting for clinical variables and was 
able  to explain up to 2.9% of the total variability in  CRP 
levels,  interestingly,  this  did  not  include  the  better  known 
rs3091244 SNP [51]. Regulation of plasma CRP levels has 
been additionally associated with promoter polymorphisms 
in the IL6 gene in various studies [52-54]. A genome-wide 
association  study  was  performed  in  6345  healthy  women 
employing 336,108 SNPs, considered as potential determi-
nants of plasma CRP in the Women’s Genome Health Study. 
This  study  identified  seven  novel  gene  loci,  including  the 
HNF-1 (hepatic nuclear factor 1alpha) and GCKR, belonging 
to  various  inflammatory  and  metabolic  pathways  that 
showed significant genome wide association with CRP lev-
els [55]. In a comprehensive  two-stage analysis of a large 
combined cohort from the PARC and the CHS study popula-
tion, one SNP, rs7953249, in the HNF-1 A gene was signifi-
cantly associated with plasma CRP levels after adjusting for 
all potential clinical covariates and rigorous statistical analy-
sis [56]. A 17A repeat allele variant in the FLAP gene has 
been associated with high CRP levels in CAD patients in a 
Taiwanese study [57]. Thus, the paradoxical findings on the 
association of CRP gene polymorphisms with CVD paint a 
similar picture to that of the IL6, wherein complex regula-
tory  mechanisms,  confounding  interactions  with  conven-
tional  risk  factors,  variable  genetic  landscape  of  the  geo-
graphic  population  under  study  and  presence/absence  of 
HWE that have not been adequately addressed in some of 
these studies, could possibly explain the vagaries in the study 
findings.  
TNF-α Gene Polymorphisms 
  The tumor necrosis factor is yet another important cyto-
kine that participates in the inflammatory reaction and has 
been  attributed  with  modulation  of  CVD  risk.  Polymor-
phisms  in  the  TNF-α  and  its  receptor  genes  (TNFR1& 
TNFR2)  and  the  gene  for  TNF-alpha  converting  enzyme 
(TACE  or  ADAM17),  that  mainly  controls  the  rate  of  
its  shedding  from  cell  surface,  have  been  investigated  in  
the  various  studies.  The  –308  G>A  (rs3091256)  promoter  
variant  has  received  the  most  attention  and  has  shown  
contradictory associations in the development of CAD [58-
60] in a population specific  manner. Others have reported 
association  with  CAD  in  the  presence  of  specific  co-
morbidities  such  as  obesity,  high  systolic  BP  and  plasma 
insulin levels [61] as well as the metabolic syndrome pheno-
type [62]. The A allele has also been independently associ-
ated with obesity in a Spanish study [63], insulin resistance 
in  obese  subjects  in  an  Australian  study  [64]  and  plasma 
CRP levels in the HERITAGE study [65]. Variations in the 
ADAM17 gene have been shown to be marginally associated 
with high plasma TNF- α levels as well as risk of cardiovas-
cular death in a prospective cohort of 1400 individuals en-
rolled  in  the  ATHEROGENE  study  [66].  Analysis  of  the 
TNF superfamily 4 (TNFSF4) gene variation showed limited 
association of these variants with CVD in Women in a pro-
spective, all-white, WHS cohort comprising of 344 incident 
CVD cases and 2254 control participants who were followed 
up for10 years [67, 68]. 
  With regard to some of the other pro-inflammatory cyto-
kine genes, the Interleukin-1 (IL1) gene cluster and the IL18 
and  its  receptor  (IL18R1  &  IL18RAP-receptor  accessory 
protein) have been investigated in a few studies. While there 
is no debate that their levels may be elevated in patients with 
CAD who exhibit a strong inflammatory response, the direct 
association of genetic variants within these genes with CVD 
has been largely negative [69, 70] except in limited studies 
[71].  Baseline  levels  of  IL-18  were  higher  among  healthy 
women in a nested case-control study who subsequently de-
veloped  CVD.  The  RR  for  future  CVD  event  was  2.53 
among individuals in the highest quartile of IL-18 levels as 
compared to those in the lowest quartile. While that risk was 
attenuated after adjustment for traditional cardiovascular risk 
factors, those with IL-18 levels at or above the 90th percen-
tile threshold remained at elevated risk even after adjustment 
[72].  Similarly,  while  IL10  has  been  known  to  exert  an  
anti-inflammatory effect and lowered risk of coronary events 
in patients with unstable angina [73, 74], no direct associa-
tion has been reported with the IL0 polymorphisms in the 
modulation of CAD risk. 
  Family-based linkage studies and genome-wide associa-
tion studies have gained immense popularity and attention in 
the last decade. Such studies involving a consortium of mul-
tiple reputed institutions have a combined power of efficient, 
high-throughput  technologies  backed  by  ample  financial 
resources to scan over 100 K – 1 million variants spanning 
across the entire genome in an unbiased manner, and have 
been  able  to  identify  interesting  and  novel  loci  associated 
with  CAD [75-78]. Studies that have involved  a restricted 
clinical phenotype such as MI have had better success than 
others that have investigated an ‘all-inclusive CAD pheno-
type’, which may represent gradient as well as overlapping 
clinical  presentations  with  inadequate  distinction  between 
them. Linkage studies on biomarkers of vascular inflamma-
tion, namely CRP, IL6, MCP-1, sICAM in the Framingham 
Heart Study has shown that multiple genes such as SELE, 
SELP and CRP on chromosome 1 that influence their levels 
and may have a potential role in the development of CVD 
[43]. Analysis involving quantitative trait loci (QTL), as in 
the Quebec family study, has identified novel loci for CRP 
on 12p11.23 (P = 0.001) and 12q15 (P = 0.0005) and for IL-
6  on  14q12 (P  =  0.002).  However,  none  of  these  loci  re-
mained  significant  after  adjusting  for  BMI  [79].  In  the 
HERITAGE  family  study,  strong  evidence  of  linkage  was 
observed on chromosome 20q13 and suggestive evidence on 
several other chromosomal loci implicating multiple loci for 
regulating inflammatory response [80]. Genome wide scan 
with  microsatellite  markers  in  hypertensive  subjects  have 
identified QTL for CRP on chromosome 10q22 and 21 [81]. 
While ‘stand-alone’ association studies do contribute to the 
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association  studies  have  the  strength  in  sample  size  as  
well as sophisticated statistical methods that can adjust for 
the effect of multiple confounding factors and can therefore 
add tremendous value towards delineating of the molecular 
basis of CVD.  
  An  overview  on  these  findings  carried  out  mainly  in 
Caucasian populations, however reveal that there is limited 
cross-race  repeatability.  While  clinical  heterogeneity,  
variable pathological settings arising out of confounding co-
morbidities and ethnicity have been some of the key issues 
on one hand, technical matters such as SNP selection based 
on  the  Hapmap  data  that  has  limited  SNP  coverage,  have 
added to the differences in study findings.  
  It is worthwhile to ponder that various implicated puta-
tive CAD loci that have attained genome wide significance 
have been  linked to both  cholesterol  metabolism (PCSK9, 
LDLR,  LPA)  [76,  78,  82]  and  to  inflammation  (HNF-1, 
CXCL12) [75, 76]. Clinical studies have shown that while 
lipid levels relate to plaque build-up in the artery, inflamma-
tory  response  preempts  plaque  instability,  rupture  and 
thrombosis. However, both lipid metabolism and inflamma-
tion are complex, independent yet interdependent processes 
that  can  modulate  CVD  risk  in  a  clinical  setting.  While  
the various statin trials on one hand suggests this link, the  
experimental  observations  published  by  Kleeman  et  al.  in 
2007 serve as a true litmus test to this ongoing relationship 
between lipids and inflammation [83]. Through application 
of systems biology tools of transcriptomics and metabolom-
ics, the authors have shown that based on the level of choles-
terol  diet  intake  in  the  ApoE  Leiden  transgenic  mice,  the 
liver switches from a resilient ‘low cholesterol stress state’ to 
a  predominantly  ‘inflammatory  state’  and  this  intricate 
switching  is  controlled  by  common  transcriptional  regula-
tors,  thereby  providing  a  rationale  for  an  interrelationship 
between the two processes.  
CONCLUSIONS 
  From  the  various  genetic  studies  discussed  above,  it  
appears that consideration towards a study design that ade-
quately addresses issues such as sample size, sample compo-
sition based on stringent clinical criteria, allelic frequencies, 
HWE,  LD  distribution  and  mode  of  inheritance  would  be 
critical factors that can govern the successful outcome of the 
study. In addition, the future course of design for improved 
risk stratification should bear in mind the presence of a mul-
tiple  loci  /genes that include overlapping atherothrombotic 
pathways, which act in tandem to modulate the inflammatory 
milieu  of  the  individual  against  the  background  of  well-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  (1).  Schematic  model  incorporating  various  atherothrombotic  risk  factors  and  associated  genes  for  enhanced  cardiovascular  risk  
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established  risk  factors  (Fig.  1).  Sensitive  proteomic  plat-
forms such as the bead-based arrays facilitate the simultane-
ous detection of multiple, low abundant proteins in circula-
tion which when combined with the genetic profile generated 
from ‘chip-based’ gene arrays, can define an ‘atherosclerotic 
bionetwork’ that can refine our quest towards development 
of a robust risk stratification tool for cardiovascular disease. 
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Examination Survey 
OR  =  Odds Ratio 
PARC  =  Pharmacogenomics  and  Risk  of 
Cardiovascular Disease 
PCSK9  =  Proprotein  convertase  subtilisin/ 
kexin type 9 
PROSPER  =  Prospective Study of Pravastatin in 
the Elderly at Risk 
PAI-1  =  Plasminogen activator inhibitor 1  
RR  =  Relative Risk 
SELE  =  Selectin  E  endothelial  Adhesion 
Molecule 1 
SELP  =  Selectin  P  granule  membrane  
protein 140kDa, antigen CD62 
SNPs  =  Single nucleotide polymorphisms  
sICAM  =  Soluble  intracellular  adhesion  
molecule  
TNFα  =  Tumor necrosis factor 1 
TNFSF4  =  TNF superfamily 4  
TACE  =  TNF-alpha converting enzyme 
WGHS  =  Women’s genome health study 
WOSCOPS  =  West of Scotland Coronary Preven-
tion Study 
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